News & Updates

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.

Cognitive decline in older adults with remitted major depressive disorder appears to be slower when they receive cognitive remediation plus transcranial direct current stimulation, according to a study.

Intravenous thrombolysis with tenecteplase is noninferior to that with alteplase, with the functional outcome and safety profile being similar, according to the results of the ORIGINAL study.

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Compared with conventional therapies, exposure to tumour necrosis factor (TNF) inhibitors is associated with increased risk of inflammatory central nervous system (CNS) diseases, irrespective of background autoimmune disease or TNF inhibitor type, a recent meta-analysis has found.

In patients with recessive dystrophic epidermolysis bullosa, treatment with pregabalin appears to substantially reduce pain and itch, according to a randomized crossover trial.